Global Community

Amgen’s obesity-drug excitement may be hiding a bigger problem: key older medicines are shrinking while the company still lacks the production muscle and timing to catch the leaders in weight-loss treatments. If fast-track rules weaken and rivals keep moving faster, the business could struggle to live up to today’s high expectations.Read more

(This story appeared on my substack page around a week ago: https://open.substack.com/pub/piproberts25/p/is-microsoft-on-sale-and-its-case?r=6kjdcg&utm_campaign=post-expanded-share&utm_medium=web ) Last October, Microsoft was trading at around US$540 per share. Today it trades closer to US$385.Read more

2,282-store US off-price retailer that converts other people's inventory mistakes into an 18% return on invested capital, and it does so most reliably when the economy is worst — recessions simultaneously push shoppers toward value and flood the closeout market with distressed branded goods, which is why the business generated record free cash flow in the COVID year on collapsed earnings. The investment case is not growth; it is protected compounding at a modest rate.Read more

Start with what happened, because what happened is not an opinion. After the close on Thursday, Netflix published its second quarter results.Read more

Silver Storm Mining aims to restart a past-producing mine while it drills out a much larger project that could change the company’s scale if the work succeeds. The catch is it needs supportive silver prices, strong financing, and better metal recovery to make the longer-term upside real.Read more

Wall Street fears companies will cut tech spending and that new tools will make consulting less needed, but Accenture could be in a stronger spot than the mood suggests. If businesses still need help putting new tech into real-world use, Accenture’s push into security, cloud, and buybacks could make today’s worries look overdone.Read more

PureTech looks like a bargain on paper, but its setup may keep that value locked away: it’s listed in London while much of its work sits in the US biotech world, and big outside funding rounds can shrink what the parent ultimately owns. See why cash needs, slow-to-arrive royalty income, and a lack of bold moves like a US listing or buybacks could leave investors waiting far longer than expected.Read more

HealthCo Healthcare & Wellness REIT (ASX:HCW) · Community narrative · July 2026 My fair value: A$1.07–1.13 (exit-adjusted) · Buy under A$0.68 · Current price A$0.72 The one-line thesis The market is pricing HCW as though its hospital income is permanently halved. The evidence says the damage is 10–15% — and that gap, not the rent, is the entire return on offer.Read more

Blackrock Silver’s Nevada project looks like a rare, high-quality silver find at a time when many small miners have been sold off hard. It could draw interest from bigger miners and even tech and solar buyers, but it’s still a speculative bet that can go wrong.Read more